Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

• Main Authors: Chan Gyu Lee (Author), TaeEun Kim (Author), Sungyoul Hong (Author), Jongwan Chu (Author), Ju Eun Kang (Author), Hee Geon Park (Author), Jun Young Choi (Author), Kyoung Song (Author), Sun Young Rha (Author), Soohyeon Lee (Author), Joon-Seok Choi (Author), Sun Min Kim (Author), Hae Min Jeong (Author), Young Kee Shin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy. This study aimed to construct recombinant IFN-β-1...